A double-blind, randomized, placebo-controlled trial of Lactobacillus helveticus and Bifidobacterium longum for the symptoms of depression

被引:218
|
作者
Romijn, Amy R. [1 ,2 ]
Rucklidge, Julia J. [1 ]
Kuijer, Roeline G. [1 ]
Frampton, Chris [3 ]
机构
[1] Univ Canterbury, Dept Psychol, Christchurch, New Zealand
[2] Univ South Wales, Sch Psychol Early Years & Therapeut Studies, Treforest Campus,Innovat House, Pontypridd CF37 1DL, M Glam, Wales
[3] Univ Otago, Dept Psychol Med, Christchurch, New Zealand
来源
关键词
Probiotic; mood; anxiety; stress; gut; inflammation; immune function; vitamin D; IRRITABLE-BOWEL-SYNDROME; GUT-BRAIN COMMUNICATION; IMMUNE ACTIVATION; OXIDATIVE STRESS; VITAMIN-D; INTESTINAL MICROBIOTA; INFLAMMATORY DISEASE; MAJOR DEPRESSION; PROBIOTICS; DISORDER;
D O I
10.1177/0004867416686694
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objectives: This trial investigated whether probiotics improved mood, stress and anxiety in a sample selected for low mood. We also tested whether the presence or severity of irritable bowel syndrome symptoms, and levels of proinflammatory cytokines, brain-derived neurotrophic factor and other blood markers, would predict or impact treatment response. Method: Seventy-nine participants (10 dropouts) not currently taking psychotropic medications with at least moderate scores on self-report mood measures were randomly allocated to receive either a probiotic preparation (containing Lactobacillus helveticus and Bifidobacterium longum) or a matched placebo, in a double-blind trial for 8weeks. Data were analysed as intent-to-treat. Results: No significant difference was found between the probiotic and placebo groups on any psychological outcome measure (Cohen's d range=0.07-0.16) or any blood-based biomarker. At end-point, 9 (23%) of those in the probiotic group showed a 60% change on the Montgomery-angstrom sberg Depression Rating Scale (responders), compared to 10 (26%) of those in the placebo group ( p=ns). Baseline vitamin D level was found to moderate treatment effect on several outcome measures. Dry mouth and sleep disruption were reported more frequently in the placebo group. Conclusions: This study found no evidence that the probiotic formulation is effective in treating low mood, or in moderating the levels of inflammatory and other biomarkers. The lack of observed effect on mood symptoms may be due to the severity, chronicity or treatment resistance of the sample; recruiting an antidepressant-naive sample experiencing mild, acute symptoms of low mood, may well yield a different result. Future studies taking a preventative approach or using probiotics as an adjuvant treatment may also be more effective. Vitamin D levels should be monitored in future studies in the area. The results of this trial are preliminary; future studies in the area should not be discouraged.
引用
收藏
页码:810 / 821
页数:12
相关论文
共 50 条
  • [21] Applicability of Press Needles to a Double-blind Trial A Randomized, Double-blind, Placebo-controlled Trial
    Miyazaki, Shougo
    Hagihara, Akihito
    Kanda, Ryo
    Mukaino, Yoshito
    Nobutomo, Koichi
    CLINICAL JOURNAL OF PAIN, 2009, 25 (05): : 438 - 444
  • [22] Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial
    McClernon, F. Joseph
    Hiott, F. Berry
    Westman, Eric C.
    Rose, Jed E.
    Levin, Edward D.
    PSYCHOPHARMACOLOGY, 2006, 189 (01) : 125 - 133
  • [23] Effects of Bifidobacterium longum CLA8013 on bowel movement improvement: a placebo-controlled, randomized, double-blind study
    Okada, Keisuke
    Takami, Daisuke
    Makizaki, Yutaka
    Tanaka, Yoshiki
    Nakajima, Shunji
    Ohno, Hiroshi
    Sagami, Toru
    BIOSCIENCE OF MICROBIOTA FOOD AND HEALTH, 2023, 42 (03) : 213 - 221
  • [24] Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial
    F. Joseph McClernon
    F. Berry Hiott
    Eric C. Westman
    Jed E. Rose
    Edward D. Levin
    Psychopharmacology, 2006, 189 : 125 - 133
  • [25] Double-blind, placebo-controlled trial of pioglitazone for bipolar depression
    Aftab, Awais
    Kemp, David E.
    Ganocy, Stephen J.
    Schinagle, Martha
    Conroy, Carla
    Brownrigg, Brittany
    D'Arcangelo, Nicole
    Goto, Toyomi
    Woods, Nicole
    Serrano, Mary Beth
    Han, Huiqin
    Calabrese, Joseph R.
    Gao, Keming
    JOURNAL OF AFFECTIVE DISORDERS, 2019, 245 : 957 - 964
  • [26] VIQUALINE IN RESISTANT DEPRESSION - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    FARAVELLI, C
    ALBANESI, G
    SESSAREGO, A
    NEUROPSYCHOBIOLOGY, 1988, 20 (02) : 78 - 81
  • [27] Evaluation of Insomnia Symptoms in a Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial of Zuranolone in Postpartum Depression
    Deligiannidis, Kristina
    Huang, Ming-Yi
    Suthoff, Ellison
    Acaster, Sarah
    Fridman, Moshe
    Gunduz-Bruce, Handan
    Lasser, Robert
    Bonthapally, Vijayveer
    Kanes, Stephen J.
    Werneburg, Brian
    BIOLOGICAL PSYCHIATRY, 2021, 89 (09) : S91 - S91
  • [28] Effect of ritanserin on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial
    Akhondzadeh, Shahin
    Malek-Hosseini, Mojgan
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 (02) : 304 - 304
  • [29] The clinical effect of benesco™ on reflux symptoms: A double-blind randomized placebo-controlled trial
    Kuipers, Thijs
    Oude Nijhuis, Renske A. B.
    Schuitenmaker, Jeroen M.
    Bredenoord, Albert J.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2023, 35 (10):
  • [30] Effect of pramipexole on RLS symptoms and sleep: A randomized, double-blind, placebo-controlled trial
    Ferini-Strambi, Luigi
    Aarskog, Dagfinn
    Partinen, Markku
    Chaudhuri, K. Ray
    Sohr, Mandy
    Verri, Daniela
    Albrecht, Stefan
    SLEEP MEDICINE, 2008, 9 (08) : 874 - 881